Q1 2020 Biogaia AB Earnings Call Transcript
()-&
Yes, good morning, everybody, and welcome to BioGaia Interim Management Statement Q1 2020. I hope all of you are doing fine and keeping safe in these difficult circumstances. So today, I'm going to go through our business executive summary, and then Alexander, our BioGaia's CFO, is going to take you through our financials. And as mentioned before, we will take your question at the end of this presentation.
Next page, please. So how did our Q1 look like in a nutshell? So first of all, our sales increased by 7%, which is mainly driven by the sales of our Paediatrics product and mainly thanks to our Protectis drop for babies. Regarding the Adult segment, we have an increase as well. But in that case, it is mainly driven by Protectis tablet and to a certain extent by Gastrics (sic) [Gastrus] tablets.
Regarding the sales per region, we have a very strong sales growth in EMEA, plus 14%; a decrease of sales in APAC, minus 6%; and a slight decrease in Americas with minus 3
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
